Enzymatic test to measure aging-related AGE/ALEs in people
Official title: Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adducts
Funded at Revel Pharmaceuticals INC. · NIH-11393659 · Data updated 2026-11-12
A family-friendly, affordable enzyme-based test could quickly measure aging-related molecules (AGEs/ALEs) in samples to help researchers study aging and related diseases.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Revel Pharmaceuticals INC. NIH-funded |
| Lab location | 1 site (San Francisco, UNITED STATES) |
| Project start | August 15, 2023 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $923,550 |
| NIH project number | 5R44AG084351-03 |
| Project ID | NIH-11393659 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include individuals whose age-related conditions or aging biomarkers would be studied using AGE/ALE measurements, or patients contributing samples for research.
✕Less likely to help
People not involved in aging studies or those without samples relevant to AGE/ALEs may not directly benefit.
What this research studies
This grant builds a simple, low-cost enzymatic assay to detect advanced glycation and lipoxidation end products in biological samples. It aims to replace expensive, labor-intensive methods with a rapid tool accessible to many researchers and clinics. By enabling easier measurement of AGE/ALEs, the project could accelerate studies on aging and age-related diseases and move science toward practical interventions.
Why it matters
Potential benefit: If successful, this tool could speed up aging research and enable broader access to AGE/ALE measurement for scientists and clinicians.
How similar studies have gone: Previous methods are costly or unreliable; this enzymatic approach represents a potentially more accessible alternative, with early prototypes already developed.
Where this research is happening
-
Revel Pharmaceuticals INC.
San Francisco, United States Active
Researchers
- Principal investigator: Cravens, Aaron — Revel Pharmaceuticals INC.
- Study coordinator: Cravens, Aaron
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.